Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 4 min read

What is tau pathology?

Tau pathology refers to the abnormal aggregation and hyperphosphorylation of the microtubule-associated protein tau, a hallmark of Alzheimer's disease and related tauopathies. This article outlines the molecular underpin

peptides-pro Editorial

What is tau pathology?

Tau pathology is the term for the abnormal accumulation of hyperphosphorylated tau protein into insoluble aggregates, including neurofibrillary tangles (NFTs), which are a defining neuropathological feature of Alzheimer's disease (AD) and other tauopathies such as frontotemporal lobar degeneration (FTLD), corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP) [2][4]. Tau is a microtubule-associated protein that, under normal conditions, stabilizes neuronal microtubules; in disease states, it undergoes hyperphosphorylation, misfolding, and aggregation, leading to synaptic dysfunction and neurodegeneration [2].

The research on tau pathology centers on pathways involving tau phosphorylation, aggregation, and clearance, as well as downstream effects on synaptic plasticity and neuroinflammation [2][6].

Research Studies

Natural medicines and tau hyperphosphorylation in AD models

A bibliometric analysis and narrative review of natural medicines for AD identified tau hyperphosphorylation as a recurring mechanistic theme in experimental studies [1]. The review mapped research trends from 2001 to 2025 and highlighted that many natural compounds are investigated for their ability to interfere with tau phosphorylation pathways in cellular and animal models of AD [1]. However, the authors noted that the relationship between bibliometric themes and experimental evidence remains insufficiently characterized, and clinical translation is not established [1].

Medicinal plants and tau-related mechanisms in preclinical models

A comprehensive review of 15 medicinal plants and 21 active compounds reported neuroprotective activity in at least one AD-related pathway, including tau hyperphosphorylation, oxidative stress, neuroinflammation, mitochondrial dysfunction, and cholinergic deficits [2]. The evidence synthesized from in vitro, in vivo, and clinical studies indicates that these compounds can modulate tau pathology in laboratory models, but the review emphasized that current FDA-approved therapies provide only modest symptomatic relief and that safe, multi-targeted alternatives are urgently needed [2]. No human dosing or efficacy claims were made.

Targeted neuronal reprogramming and tauopathy in the P301S mouse model

In the P301S mouse model of tauopathy, targeted and intermittent expression of Yamanaka factors (YFs) in hippocampal neurons was investigated for its effects on cognitive function and neural network integrity [3]. The study reported that controlled YFs expression increased excitatory synaptic markers and rescued memory deficits and neural synchrony in these mice [3]. This research is animal-only and does not provide evidence for human application.

Davunetide (AL-108) and predicted tauopathies in a clinical pilot study

A pilot clinical study (NCT01056965) evaluated davunetide (NAP, AL-108) in patients with predicted tauopathies, including FTLD with predicted tau pathology, CBS, and PSP [4]. The primary objective was to obtain preliminary safety and tolerability data; secondary objectives included short-term changes (at 12 weeks) in clinical, functional, and biomarker measurements such as cerebrospinal fluid (CSF) tau levels, eye movements, and brain MRI [4]. This study was designed to gather preliminary data and did not test efficacy for any indication.

NAD+-mitophagy axis and neurodegeneration in aging models

A combined artificial intelligence-wet lab approach identified a pivotal role of the NAD+-mitophagy axis in aging and neurodegeneration [5]. The study hypothesized that age-dependent impairment of this axis contributes to brain aging and neurodegeneration, and it reported that nicotinamide mononucleotide (NAD+) depletion and compromised mitophagy are linked to these processes [5]. This work is reference-only and supports the broader context of tau pathology research, but it does not directly investigate tau aggregation.

Biochemical modulators of synaptic plasticity in AD

A review of biochemical modulators of synaptic plasticity in AD discussed how synaptic dysfunction is the earliest and most critical pathological feature, directly contributing to cognitive decline [6]. The review provided an integrative overview of molecular and biochemical modulators governing synaptic plasticity and their disruption in AD, including pathways that intersect with tau pathology [6]. This is a reference-only source and does not present original experimental data on tau.

Comparison of tau-targeting approaches in preclinical and clinical studies

Compound/Approach Model/Study Type Key Tau-Related Findings
Natural medicines (various) Bibliometric/narrative review of experimental studies [1] Tau hyperphosphorylation is a recurring mechanistic theme; clinical translation not established [1]
Medicinal plant compounds (21 active compounds) In vitro, in vivo, and clinical studies [2] Modulate tau hyperphosphorylation and other AD-related pathways; no human dosing or efficacy claims [2]
Yamanaka factors (YFs) P301S mouse model of tauopathy [3] Increased excitatory synaptic markers; rescued memory and neural synchrony [3]
Davunetide (AL-108) Clinical pilot study in predicted tauopathies [4] Preliminary safety and tolerability; secondary measures included CSF tau levels [4]

If you are reading this for personal health reasons

The materials and compounds discussed here are sold for laboratory research use only. We do not provide dosing, medical guidance, or recommendations for personal use. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp